138 related articles for article (PubMed ID: 29985096)
21. Benefit-Harm Analysis of Earlier Initiation of Triple Therapy for Prevention of Acute Exacerbation in Patients with COPD.
Mountain R; Duan KI; Johnson K
Ann Am Thorac Soc; 2024 Apr; ():. PubMed ID: 38578813
[No Abstract] [Full Text] [Related]
22. New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach.
Juergens LJ; Worth H; Juergens UR
Adv Ther; 2020 May; 37(5):1737-1753. PubMed ID: 32200535
[TBL] [Abstract][Full Text] [Related]
23. Comparing Glycopyrronium/Formoterol Combination Therapy With Monotherapy in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD): A Narrative Review.
Prada BS; Jadhav U; Ghewade B; Wagh P; Karnan A; Ledwani A
Cureus; 2024 Apr; 16(4):e58633. PubMed ID: 38770495
[TBL] [Abstract][Full Text] [Related]
24. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations.
Nicolini G; Scichilone N; Bizzi A; Papi A; Fabbri LM
Ther Clin Risk Manag; 2008 Oct; 4(5):855-64. PubMed ID: 19209268
[TBL] [Abstract][Full Text] [Related]
25. PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population.
Criner G; Martinez F; Gandhi H; Pyenson B; Feigler N; Emery M; Gupta U; Vaduganathan M
J Health Econ Outcomes Res; 2023; 10(1):20-27. PubMed ID: 36742194
[No Abstract] [Full Text] [Related]
26. The effect of beclomethasone-formoterol
van der Veer T; de Koning Gans JM; Braunstahl GJ; Pieters ALP; van den Berg JMW; Hoek RAS; Kamphuis LSJ; Bakker M; Dubois AVF; Aerts JGJV; van der Eerden MM
Eur Respir J; 2023 Jun; 61(6):. PubMed ID: 37263749
[No Abstract] [Full Text] [Related]
27. Initial inhaler choice in COPD: real-world evidence.
Jones T
Breathe (Sheff); 2019 Dec; 15(4):350-352. PubMed ID: 31803273
[No Abstract] [Full Text] [Related]
28. Glycopyrronium bromide cream for prevention of chronic-relapsing candidiasis of submammary folds: preliminary results of a sponsor-free study.
Veraldi S; Schianchi R; Nazzaro G
J Dermatolog Treat; 2023 Dec; 34(1):2287403. PubMed ID: 38017707
[No Abstract] [Full Text] [Related]
29. Optimizing Pharmacotherapy Management of COPD: Don't Miss the Forest for the Trees.
Bourbeau J; Bhutani M; Hernandez P; Penz E; Marciniuk DD
Am J Respir Crit Care Med; 2024 Apr; ():. PubMed ID: 38626371
[No Abstract] [Full Text] [Related]
30. Escalation and De-Escalation of Therapy in Chronic Obstructive Pulmonary Disease. Is the Inhaler Important?
Alonso-Pérez T; García-Castillo E; López-Campos JL
Arch Bronconeumol (Engl Ed); 2021 Feb; ():. PubMed ID: 33637341
[No Abstract] [Full Text] [Related]
31. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Therapy of COPD: Reasons for Optimism.
Celli BR
Chest; 2018 Dec; 154(6):1404-1415. PubMed ID: 30028967
[TBL] [Abstract][Full Text] [Related]
33. Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Frent SM; Chapman KR; Larbig M; Mackay A; Fogel R; Gutzwiller FS; Shen S; Patalano F; Banerji D; Kostikas K; Wedzicha JA
Am J Respir Crit Care Med; 2019 Jan; 199(1):43-51. PubMed ID: 30019939
[TBL] [Abstract][Full Text] [Related]
34. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
35. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
36. Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Petite SE
N Engl J Med; 2018 Aug; 379(6):591-2. PubMed ID: 30091349
[No Abstract] [Full Text] [Related]
37. In symptomatic COPD, once-daily triple vs dual therapy reduced moderate or severe exacerbations at 1 year.
Stanbrook MB
Ann Intern Med; 2018 Aug; 169(4):JC16. PubMed ID: 30128506
[No Abstract] [Full Text] [Related]
38. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
Kupczyk M; Kuna P
Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
[TBL] [Abstract][Full Text] [Related]
39. High or low impact? Triple therapy in chronic obstructive pulmonary disease.
McDonald CF; Bardin PG
Respirology; 2018 Oct; 23(10):891-892. PubMed ID: 30125432
[No Abstract] [Full Text] [Related]
40. Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.
Borghardt JM; Kloft C; Sharma A
Can Respir J; 2018; 2018():2732017. PubMed ID: 30018677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
